Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Earnings Forecast: Abbott anticipates Q4 2025 EPS of $1.50, reflecting an 11.9% year-over-year increase, indicating strong performance in its medical devices and nutrition segments.
- Diagnostics Growth: Despite revenue impacts from procurement programs in China, Abbott's diagnostics segment is expected to grow 0.8% year-over-year, demonstrating sustained global demand for routine diagnostic testing.
- Medical Device Sales Surge: The medical devices segment is projected to see a 12.5% year-over-year revenue increase, driven by diabetes care and cardiac rhythm management products, particularly following the launch and FDA approval of the Volt PFA catheter.
- Nutrition Innovation: Abbott's launch of low-sugar Glucerna and the Ensure Max Protein line is expected to contribute to a 3.3% year-over-year revenue growth in the nutrition segment, further solidifying its market position.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ABT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 106.050
Low
136.00
Averages
148.11
High
169.00
Current: 106.050
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott's Stock Drops Following Earnings Report as CEO Purchases $2 Million in Shares.
- Stock Performance: Abbott Laboratories experienced its largest stock drop in over 20 years following the release of its fourth-quarter earnings report.
- CEO's Confidence: Despite the significant decline in share value, the company's chief executive remains optimistic about the stock's future.
Continue Reading
Abbott Shares Snap Six-Day Losing Streak with 1.2% Gain
- Stock Rebound: Abbott shares closed 1.2% higher at $108.77 on Monday after six consecutive days of losses, indicating a short-term sentiment rebound despite an overall weak trend.
- Revenue Underperformance: The company reported lower-than-expected revenue for Q4 2025, particularly in its Nutrition segment, leading to a 10% drop in stock price last Thursday, reflecting market concerns about its growth potential.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, Abbott holds a Hold rating with a score of 3.06, indicating strong profitability prospects (A+) but weak growth factors (D-), which may affect investor confidence.
- Executive Buy: Abbott's Chairman and CEO Robert Ford recently purchased 18,800 shares worth over $2 million, signaling executive confidence in the company's future, which may attract more investor interest.
Continue Reading